Core Viewpoint - The launch of the world's first "Hepatitis B Cure AI Assistant" by Yidu Technology in collaboration with Chongqing Medical University Second Affiliated Hospital aims to provide a comprehensive closed-loop service for Hepatitis B management, addressing issues such as fragmented information and inefficient clinical research recruitment [1][2]. Group 1: AI Assistant Features - The AI assistant is built on a medical domain-specific large model and offers a one-stop service covering screening, diagnosis, treatment, follow-up, and research [1]. - It operates on a smart management system that integrates clinical pathways and utilizes retrieval-augmented generation (RAG) technology to create a digital support system throughout the disease management process [1][2]. - The assistant acts as a "personal health manager," enabling continuous intelligent services for patients, including follow-ups, personalized education, health consultations, and appointment reminders [1]. Group 2: Clinical Collaboration and Data Integration - The AI assistant enhances clinical collaboration by covering the entire process from high-risk population screening to long-term follow-up and rehabilitation guidance, while also bridging the gap between research and clinical data [2]. - The collaboration between Yidu Technology and Chongqing Medical University has led to the establishment of a high-quality "Hepatitis B Specialty Database," which supports the AI assistant's capabilities [2]. - The assistant's effectiveness has been validated in clinical settings, demonstrating its ability to provide personalized risk assessments and decision support based on complex medical logic [2]. Group 3: Future Developments - The AI assistant is currently undergoing testing on both mobile and computer platforms, with plans for patients to access pre-consultation services and expert recommendations through a user-friendly interface [3]. - Yidu Technology plans to explore innovative services such as specialized large models and digital avatars for doctors, expanding the boundaries of intelligent management in the field of liver disease [3].

Core Insights - The National Healthcare Security Administration (NHSA) released a guideline focusing on pricing for surgical and treatment auxiliary operations, emphasizing advanced medical technologies such as 3D printing and robotic surgery [1][2] Group 1: Pricing Guidelines - The guideline establishes 37 pricing items, 5 additional charges, and 1 expansion item, aiming to standardize pricing for innovative medical technologies [1] - Pricing is categorized based on the level of robotic participation in surgeries, with three tiers: navigation, participation, and precision execution, promoting the use of advanced surgical robots in complex procedures [1][2] Group 2: Impact on Healthcare - The pricing initiative is expected to facilitate the transition of remote surgeries from experimental stages to practical applications, benefiting patients, healthcare institutions, and pharmaceutical companies [2] - The guideline aims to enhance the accessibility of quality medical resources across regions and innovate the hierarchical diagnosis and treatment model [2] Group 3: Cost Considerations - The guideline specifies that auxiliary operation fees should reflect the clinical value and usage costs of consumables, prohibiting simultaneous charges for disposable materials and corresponding auxiliary operation fees [2] - To ensure quality control and traceability in robotic and remote surgeries, the guideline includes requirements for storing and uploading medical data and equipment operation records, with penalties for non-compliance [2]

Core Insights - The article discusses the increasing pressure on global healthcare systems due to aging populations and chronic disease burdens, highlighting inefficiencies in patient care processes, particularly in China [2] - Recent studies demonstrate that AI chatbots based on large language models (LLMs) can significantly enhance healthcare delivery by improving patient engagement and streamlining care transitions [3] Study 1: PreA Chatbot - The PreA chatbot, developed to assist patients transitioning from primary to specialist care, was tested in a randomized controlled trial involving 2,069 patients across 24 departments in two major hospitals in Western China [6][7] - Key findings include a 28.7% reduction in consultation time for patients using PreA, with average times decreasing from 4.41 minutes to 3.14 minutes, and a 113.1% improvement in the perceived usefulness of referral reports by specialists [7] - The success of PreA is attributed to its co-design with local stakeholders, ensuring it meets real clinical needs and operates effectively in resource-limited settings [10] Study 2: P&P Care Chatbot - The P&P Care chatbot focuses on enhancing the primary care experience and was also tested in a randomized controlled trial involving 2,113 participants across 11 provinces in China [12][13] - The co-design approach involved community members, leading to features that cater to cultural and literacy needs, such as voice interfaces and offline capabilities [15] - The P&P Care chatbot outperformed traditional primary care methods in areas like history-taking, diagnostic accuracy, and chronic disease management [15] Common Insights - Both studies emphasize the importance of co-design in deploying AI in healthcare, which helps avoid systemic biases and ensures tools are aligned with actual needs [17] - AI tools like PreA and P&P Care are not intended to replace doctors but to handle routine tasks, allowing healthcare professionals to focus on complex decision-making and patient care [18] - The robust performance of these AI chatbots in resource-limited environments suggests they could serve as models for improving healthcare equity globally [19]

"现在我们去陌拜医生，花10秒钟介绍演示，基本上100%都会下载这个产品。" 1月中旬，在位于杭州城西的阿里健康总部，极少在媒体前露面的CTO祥志接受了《健闻咨询》的独家 专访。 大概半年前，阿里健康在手机应用商城悄无声息地上线了一款名为"氢离子"的AI原生APP，主要面向医 生群体，功能定位类似于美国的医疗AI独角兽——OpenEvidence。 那时候，大洋彼岸的OpenEvidence刚完成B轮融资，估值35亿美元，"医生版ChatGPT"的故事尚未完全 展开。 对于以医药电商和C端用户为基本盘的阿里健康来说，这更像是一次未知的冒险——为医生提供循证医 学下的决策支持，并不在其主营业务的雷达范围之内。相比之下，预问诊、医生数字分身，乃至院外场 景中的AI健康管家，都能为传统的线上药品交易带来更多的商业机会和增长空间。 此后的半年时间里，阿里健康不做产品宣发，婉拒媒体采访，把"氢离子"的曝光度降到最低。他们只做 了一件事——邀请不同层级的医生进行产品内测，再根据反馈迭代优化。 如果我们把视线再拉长一点，从2022年底ChatGPT引爆大语言模型的技术浪潮以来，阿里健康就似乎一 直潜伏于水面之下：不搞自研大 ...

Core Viewpoint - The resignation of non-independent director Wang Wenhui from the board of Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. is confirmed, and it will not affect the company's operations or board composition [1][2]. Group 1: Resignation Details - Wang Wenhui submitted a written resignation due to personal work reasons, resigning from his position as a director and a member of the Strategic Committee of the third board [1]. - His resignation is effective immediately upon delivery to the board and will not lead to a reduction in the number of board members below the legal minimum [1][2]. Group 2: Company Response - The company expresses gratitude for Wang Wenhui's contributions during his tenure and confirms that he has no shares in the company at the time of his resignation [2]. - The company will proceed with the necessary procedures to elect a new non-independent director in accordance with relevant laws and regulations [2].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （「本公司」） （於中華人民共和國成立的股份有限公司） 警告 Anhui Zhongji Guoyi Medical Technology Co., Ltd. 安徽中技國醫醫療科技股份有限公司 本公告乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委 員會（「證監會」）的要求而刊發，僅用作提供資料予香港公眾人士。閣下閱覽本 公告，即代表閣下知悉、接納並向本公司、其獨家保薦人、整體協調人、顧問 或包銷團成員表示同意： – 1 – (a) 在聯交所網站登載本公告，並不會引致本公司、其獨家保薦人、整體協調 人、顧問或包銷團成員須於香港或任何其他司法權區進行發售或配售活 動的責任。概不保證本公司將會進行發售或配售； (b) 本公告所涉及的上市申請並未獲批准，聯交所及證監會或會接納、發回或 拒絕有關的公開發售及╱或上市申請； (c) 本公告不應被視為誘使認購或購買任何證券，亦無意構成該等勸誘； (d) ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本的全部或任何部分內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 Anhui Zhongji Guoyi Medical Technology Co., Ltd. 安徽中技國醫醫療科技股份有限公司 （「本公司」） （於中華人民共和國成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、其獨家保薦人、整體協調人、顧問及包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據本公司向香港公司註冊 處處長登記的文件作出投資決定，文件將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據 本文件中的資料作出任何投資決定； (b) 在聯交所網 ...

Group 1 - Ant Group's Aifoo has upgraded its PC platform and launched the DeepSearch feature, providing free professional services to medical professionals, significantly reducing their daily workload [1] - Aifoo has become a phenomenon in the domestic C-end AI health management application market, with over 30 million monthly active users and an average of over 10 million health inquiries per day, achieving deep penetration in third-tier cities and below [1] - Aifoo integrates three core functions: health Q&A, health companionship, and health services, collaborating with 300,000 doctors and over 5,000 medical institutions to offer one-stop services such as appointment booking, medication purchasing, report interpretation, and health data analysis [1] Group 2 - Meinian Health is collaborating with Ant Group and Damo Academy on "one scan, multiple checks," multi-disease intelligent screening, and AI health report interpretation, aiming to transform low-frequency health check-ups into high-frequency health management [2] - Dian Diagnostics has integrated the "Ant Medical Large Model All-in-One Machine" into its health management institutions, generating main inspection reports and tiered warnings to reduce costs and increase efficiency, enhancing order and service value as the Aifoo ecosystem expands [2]

Core Viewpoint - The company, Chuangyue Huikang, has been actively collaborating with Alibaba and Ant Group since 2018, focusing on cloud computing, mobile payments, AI, and healthcare scenarios to enhance patient experience and develop innovative solutions in the healthcare sector [1][2]. Group 1: Collaboration Details - Since 2018, the company has engaged in a series of business and technical collaborations with Alibaba's Ant Financial and Alibaba Cloud [2]. - The partnerships leverage each party's strengths to create a "future healthcare" model centered on patient experience, integrating technologies such as mobile payments, credit systems, big data, and artificial intelligence [2]. - Recent efforts have focused on developing AI solutions for healthcare, including medical AI solutions, computing integration, and research innovation scenarios [2]. Group 2: Strategic Goals - The collaboration aims to promote mutual benefits and complementary advantages, driving the development of AI solutions tailored for healthcare clients [2]. - The companies are jointly working on market expansion strategies within the healthcare sector [2].

Core Insights - Ant Group's Aifu has upgraded its PC platform and launched the DeepSearch feature, aiming to create a Chinese version of "Open Evidence" to provide free professional services for doctors, medical students, and grassroots healthcare workers [1][2] User and Doctor Engagement - The upgraded PC platform offers two main capabilities: health consultation and DeepSearch, serving as an AI assistant for doctors in literature search, clinical diagnosis, and research, significantly reducing their daily workload [1][2] - Aifu App is the largest health management app in China, with daily user inquiries exceeding 10 million [1][2] - Leveraging its self-developed Ant Medical Health Model, Aifu has opened "AI avatar" technology to over 1,000 doctors, who can provide 24/7 online health consultation through their AI avatars on the app [1][2]